Company Name
ACELYRIN, INC. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US00445A1007
CIK:
0001962918
Currency:
USD
Full Time Employees:
83
Phone:
805 456 4393
Website:
https://www.acelyrin.com
Fiscal Year End:
December
IPO Date:
May 04, 2023
Description:
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.
Address:
4149 Liberty Canyon Road, Agoura Hills, CA, United States, 91301